Financials InflaRx N.V.

Equities

IFRX

NL0012661870

Biotechnology & Medical Research

Market Closed - Nasdaq 16:30:01 2024-05-03 EDT 5-day change 1st Jan Change
1.38 USD 0.00% Intraday chart for InflaRx N.V. +3.76% -15.34%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 92.2 116.3 185 128 86.96 75.43 - -
Enterprise Value (EV) 1 -22.43 35.68 74.37 44.07 86.96 20.99 64.84 75.43
P/E ratio -1.72 x -3.27 x -3.81 x -4.32 x -1.89 x -1.4 x -1.49 x -1.89 x
Yield - - - - - - - -
Capitalization / Revenue - - - - 1,378 x 81 x 34 x 47.1 x
EV / Revenue - - - - 1,378 x 22.5 x 29.3 x 47.1 x
EV / EBITDA 399,872 x -1,073,762 x -1,583,529 x -1,392,696 x - - - -
EV / FCF 0.51 x -0.97 x -1.86 x -1.3 x - -0.33 x -0.95 x -5.62 x
FCF Yield 195% -103% -53.8% -76.9% - -302% -105% -17.8%
Price to Book 0.86 x 1.49 x 1.76 x 1.45 x - - - -
Nbr of stocks (in thousands) 26,105 28,228 44,186 44,204 58,883 58,883 - -
Reference price 2 3.532 4.118 4.187 2.897 1.477 1.281 1.281 1.281
Announcement Date 20-04-29 21-03-25 22-03-24 23-03-22 24-03-21 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 - - - - 0.0631 0.9317 2.216 1.6
EBITDA -56.11 -33.23 -46.97 -31.64 - - - -
EBIT 1 -56.77 -33.94 -47.63 -32.24 -44.91 -58.99 -66.94 -57.3
Operating Margin - - - - -71,181.01% -6,331.32% -3,020.28% -3,581.33%
Earnings before Tax (EBT) 1 -53.25 -33.98 -45.63 -29.48 -42.67 -60.52 -66.9 -56.61
Net income 1 -53.25 -33.98 -45.63 -29.48 -42.67 -58.06 -62.86 -56.32
Net margin - - - - -67,629.62% -6,232.33% -2,836.03% -3,519.75%
EPS 2 -2.050 -1.260 -1.100 -0.6700 -0.7800 -0.9175 -0.8625 -0.6767
Free Cash Flow 1 -43.8 -36.62 -39.97 -33.91 - -63.31 -68.02 -13.42
FCF margin - - - - - -6,795.22% -3,069.17% -838.81%
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 20-04-29 21-03-25 22-03-24 23-03-22 24-03-21 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 - - - - - - - - 0.0608 0.00229 0.1323 0.1227 0.129 0.5477 -
EBITDA -12.57 -12.83 -14.71 - - - - - - - - - - - -
EBIT 1 -12.73 -13 -14.86 -1.087 -8.594 -7.699 -10.59 -9.856 -11.15 -13.31 -13 -15.15 -15.65 -15.26 -13.98
Operating Margin - - - - - - - - -18,340.21% -581,058.52% -9,820.4% -12,349.94% -12,130.49% -2,786.41% -
Earnings before Tax (EBT) 1 -12.05 -12.67 -14 0.4654 -7.922 -8.026 -11.08 -8.202 -7.451 -15.93 -13.44 -15.56 -16.01 -15.57 -13.29
Net income 1 -12.05 -12.67 -14 0.4654 -7.922 -8.026 -11.08 -8.202 -7.451 -15.93 -13.25 -14.84 -15.18 -14.85 -13.29
Net margin - - - - - - - - -12,255.61% -695,640.17% -10,015.49% -12,096.89% -11,764.92% -2,710.62% -
EPS 2 -0.2700 -0.2900 -0.3200 0.0100 -0.1800 -0.1800 -0.2500 -0.1400 -0.1300 -0.2800 -0.2225 -0.2475 -0.2350 -0.2150 -0.1900
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 21-11-05 22-03-24 22-05-12 22-08-05 22-11-09 23-03-22 23-05-11 23-08-10 23-11-01 24-03-21 - - - - -
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 115 80.6 111 84 - 54.4 10.6 -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -43.8 -36.6 -40 -33.9 - -63.3 -68 -13.4
ROE (net income / shareholders' equity) -41.2% -36.7% -49.8% -30.5% - - - -
ROA (Net income/ Total Assets) -37.9% -32.4% -42.8% - - - - -
Assets 1 140.4 104.9 106.7 - - - - -
Book Value Per Share 4.120 2.760 2.380 2.000 - - - -
Cash Flow per Share - -1.350 -0.9600 -0.7600 - - - -
Capex 1 0.59 0.09 0.04 0.16 - 0.09 0.1 0.12
Capex / Sales - - - - - 9.55% 4.42% 7.38%
Announcement Date 20-04-29 21-03-25 22-03-24 23-03-22 24-03-21 - - -
1EUR in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.281 EUR
Average target price
7.372 EUR
Spread / Average Target
+475.48%
Consensus
  1. Stock Market
  2. Equities
  3. IFRX Stock
  4. Financials InflaRx N.V.